However, in the research process, some researchers have found that targeting the colony-stimulating factor 1 receptor (CSF-1R) to reduce macrophage polarization towards M2 and block GBM malignant progression resulted in acquired resistance in animal models [25], and the efficacy was found to be very limited in clinical trials [26]. This evidence concerns the gene CSF1R and glioblastoma.